SAN DIEGO--(BUSINESS WIRE)--Libra Therapeutics, Inc. today announced the appointment of Philip Lambert, Ph.D., as the company’s first chief scientific officer. With more than 25 years of drug discovery and development expertise in the areas of neuroscience, metabolic, inflammatory, and orphan diseases and a neuroscientist by training, Dr. Lambert will lead Libra’s development of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Dr. Lambert joins Libra from CENTOGENE, where he was Chief Scientific Officer and led the company’s drug discovery operation.